星空游戏网站免费进入|星空彩票电脑版

神经药理学报››2014,Vol. 4››Issue (4): 36-41.

帕金森病患者下尿路功能障碍的治疗进展

吴志刚，沈丽霞

星空游戏网站免费进入药学系，张家口，075000，中国

出版日期:2014-08-26发布日期:2015-01-20
通讯作者:沈丽霞，女，教授；研究方向：神经药理学；Tel：+86-0313-4029305，E-mail：shenlixiacn@sina.com
作者简介:吴志刚，男，讲师；研究方向：神经药理学；Tel：+86-0313-4029305，E-mail：wuzhigang1982@126.com
基金资助:

河北省教育厅项目（No. Z2012014），星空游戏网站免费进入校级课题项目（No. Q2013028）

Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease

WU Zhi-gang，SHEN Li-xia

Department of Pharmacy, Hebei North University, Zhangjiakou, 075000, China

Online:2014-08-26Published:2015-01-20
Contact:沈丽霞，女，教授；研究方向：神经药理学；Tel：+86-0313-4029305，E-mail：shenlixiacn@sina.com
About author:吴志刚，男，讲师；研究方向：神经药理学；Tel：+86-0313-4029305，E-mail：wuzhigang1982@126.com
Supported by:

河北省教育厅项目（No. Z2012014），星空游戏网站免费进入校级课题项目（No. Q2013028）

摘要/Abstract

摘要：帕金森病是一种渐进的中枢神经系统退行性疾病。尽管帕金森病是以运动症状为主要特征，但其非运动症状也逐渐受到重视。帕金森病患者常常会出现下尿路功能障碍，主要症状包括尿急、尿频、夜尿症、急迫性尿失禁等，严重影响患者的生活质量。本文综述目前临床常用的治疗策略以及一些潜在的治疗方法，希望这些治疗能够最大限度地提高患者的生活质量。

关键词:帕金森病,治疗,下尿路,膀胱,尿道,功能障碍

Abstract:Parkinson’s disease is a progressive degenerative disorder of the central nervous system. Although motor symptoms are a predominant feature of the condition, non-motor symptoms have also been recognized. Lower urinary tract dysfunction is frequently present in patients affected with Parkinson’s disease. Symptoms such as urgency, frequency, nocturia and urge incontinence significantly impact the patient’s quality of life. We present an overview of current and prospective treatment strategies. These treatments might be beneficial in maximizing the patients’ quality of life.

Key words:Parkinson&,rsquo,s disease,treatment,lower urinary tract,bladder,urethra,dysfunction

中图分类号:

R964

吴志刚，沈丽霞.帕金森病患者下尿路功能障碍的治疗进展[J]. 神经药理学报, 2014, 4(4): 36-41.

WU Zhi-gang，SHEN Li-xia.Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease[J]. Acta Neuropharmacologica, 2014, 4(4): 36-41.

参考文献

[1] Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011, 17(2):77-83.

[2] Badri AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinson's disease. Curr Urol Rep. 2014, 15(9):435-443.

[3] Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008, 9(6):453-466.

[4] 胡钢. 帕金森病膀胱尿道功能障碍的研究[D]. 重庆,重庆医科大学,2007:21-22.

[5] 姜良真. 耻骨上经膀胱前列腺切除术与耻骨后前列腺切除术手术疗效比较及神经原性膀胱的尿动力学分析[D]. 天津,天津医科大学,2009:50-51.

[6] Aranda B, Cramer P. Effect of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993, 12(3): 203-209.

[7] Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004, 23(7):689-696.

[8] Kuno S, Mizuta E, Yamasaki S, et al. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004, 10(3):181-187.

[9] Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson’s disease. Br J Urol. 1985; 57(6):652-656.

[10] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trend Neurosci. 2000; 23(10 Suppl): S2–S7.

[11] 孙颖浩. ?1受体阻滞剂治疗良性前列腺增生研究进展[J]. 中华男科学杂志,2004,10(7):483-485.

[12] Gomes CM, Sammour ZM, Bessa Junior Jd, et al. Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. Clinics (Sao Paulo). 2014, 69(12):817-822.

[13] Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997, 315(7119):1363–1364.

[14] 张辰珠,姚建. 曲司氯铵治疗膀胱过动症[J]. 世界临床药物, 2006, 27(6):359-363.

[15] 薛晓岩,于天民. 达非那新治疗特发性急迫性尿失禁30例[J]. 中国民康医学,2013,25(11):73-74.

[16] Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum toxin A on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol. 1988,139(5):919–922

[17] 陈俊男. A型肉毒毒素对神经和肌肉影响的效价研究[D].上海市, 第二军医大学,2008:1-2.

[18] Kapoor S, Bourdoumis A, Mambu L, et al. Effective management of lower urinary tract dysfunction in idiopathic Parkinson’s Disease. Int J Urol. 2013; 20(1):79–84.

[19] Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011, 186(3):960–964.

[20] Cone EB, Ellsworth P. Neurogenic detrusor overactivity: an update on management options. R I Med J. 2013, 96(4):38–40.

[21] Sakakibara R, Ito T, Uchiyama T, et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int. 2008, 81(3):335–339.

[22] Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord.1995, 10(3):337–340.

[23] Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clincal development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013, 386(3):177–183.

[24] 何鹏彬,查培金,徐东萍. 磷酸二酯酶-5抑制剂治疗良性前列腺增生所致下尿路症状的研究进展[J].中华男科学杂志,2014,20(7):651-654.

[25] Proietti S, Giannantoni A, Sahai A, et al. Overactive bladder and sexual function: a nightmare couple. BJU Int. 2012, 110(7):921–924.

[26] Ashkan K, Samuel M, Reddy P, et al. The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm. 2013, 120(4):639-642.

[27] Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord. 2002, 17 (Supple 3): S63–S68.

[28] Shimizu N1, Matsumoto S, Mori Y, et al. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo. 2007, 53(9):609-612.

[29] Phé V, Caremel R, Bart S, et al. Lower urinary tract dysfunctions in parkinsonian syndromes: a review by the Neuro-Urology Comittee of the French Association of Urology. Prog Urol.2013, 23(5):296–308.

[30] Ohannessian A, Kaboré FA, Agostini A, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson’s syndromes. Prog Urol. 2013, 23(11):936–939.

[31] Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988, 140(1):117–118.

[32] Roth B, Studer UE, Fowler CJ, et al. Benign prostatic obstruction and parkinson’s disease-should transurethral resection of the prostate be avoided? J Urol. 2009, 181(5):2209–2213.

[33] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol.2012, 44(2):415-424.

[34] 黄嘉,张庆霞,梁文蔚. 艾灸治疗帕金森病排尿障碍31例[J]. 中国中医药现代远程教育,2012,10(7):46-47.

[35] 陈义良,张小莉,周国林. 针灸推拿结合药物治疗脑外伤后综合征42例临床观察[J]. 江苏中医药,2010,42(4):53-54.

[36] 陈义良,冯为菊,张小莉. 针药结合治疗帕金森病合并膀胱过度活动症[J]. 中国针灸,2012,32(3):215-218.

帕金森病患者下尿路功能障碍的治疗进展

Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

[1]	蒋琴, 王与同, 黄宇琪, 徐梓轩, 卢应梅.放射线诱导的认知功能损伤：致病机制及治疗药物研究进展[J]. 神经药理学报, 2025, 15(3): 13-.
[2]	赵姣娇, 杨磊, 张炜.癫痫治疗的多维度研究：分子机制、临床策略与未来方向[J]. 神经药理学报, 2025, 15(3): 24-.
[3]	要祎冉, 张健东, 李炜.外泌体在靶向药物递送与疾病治疗中的应用与机制研究[J]. 神经药理学报, 2025, 15(1): 55-.
[4]	盛文才, 周月.甲泼尼龙与多西环素联合治疗方案用于肺炎支原体肺炎患儿对炎性因子及氧化应激指标的影响[J]. 神经药理学报, 2024, 14(5): 37-.
[5]	郝雪南, 杨磊, 赵文雅, 张炜.高热惊厥病因和治疗的研究进展[J]. 神经药理学报, 2024, 14(4): 42-.
[6]	朱静怡, 樊建春, 禹爱梅.普罗布考在保护神经系统中的研究现状[J]. 神经药理学报, 2023, 13(6): 50-.
[7]	程艳洁, 王鹏飞.复合乳酸菌辅助二联方案治疗幽门螺杆菌感染的效果研究[J]. 神经药理学报, 2023, 13(2): 41-.
[8]	郭宝, 刘子铭, 景永帅, 张丹参.Wnt信号通路与阿尔茨海默病的相关性及靶点研究[J]. 神经药理学报, 2023, 13(1): 56-.
[9]	司文英, 侯宇清, 孙晓静, 孟宪勇, 董晓华.基因治疗阿尔茨海默病[J]. 神经药理学报, 2022, 12(6): 51-56.
[10]	蔡雨珊, 赵帅.PPARβ/δ在神经退行性疾病中的研究进展[J]. 神经药理学报, 2022, 12(4): 41-48.
[11]	崔佩, 孙玉姣, 陈晶晶, 张馨予, 董艳红.加速重复经颅磁刺激应用的研究进展[J]. 神经药理学报, 2022, 12(3): 23-.
[12]	董露露, 王璐璐, 陈景红, 等.帕金森病异动症的影响因素及其相关机制的研究[J]. 神经药理学报, 2022, 12(2): 53-.
[13]	宋秋敬, 王娟.从肝脾论治2型糖尿病中西医研究[J]. 神经药理学报, 2022, 12(2): 58-.
[14]	张巧巧, 范荣珍, 景永帅, 张丹参.缺血性脑损伤中的线粒体质量控制[J]. 神经药理学报, 2022, 12(1): 41-47.
[15]	王家琦, 吴路路, 王禹丹, 等.CHA2DS2-VASc 评分联合中性粒细胞与淋巴细胞比值对急性STEMI患者直接PCI 后无复流的关系研究[J]. 神经药理学报, 2021, 11(6): 46-.